Recent studies have reported the presence of natural humoral and cellular immunity against Ror1 in chronic lymphocytic leukemia (CLL) patients23 and expression of high levels of Ror1 may promote cancer cell activation and survival enhancing disease progression in patients suffering from CLL24. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.